The Immunoscore (IS), introduced [6] and defined by Jérome Galon and colleagues [7], is a scoring system (from I0 to I4) based on immunohistochemistry and digital pathology; it assesses the in situ densities of two lymphocyte populations, CD3+ and CD8+ T cells, in the tumor and its invasive margin. This evidence concerns the gene CD8A and neoplasm.